Vir Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
VIR$13.65+11.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Audited Consolidated Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 86 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 88 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | 89 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | 90 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | 91 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | 92 |
| Notes to Consolidated Financial Statements | 93 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.